The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

CEO Gina Chapman is also departing the company, which plans to review options for pursuing a reverse merger or other business ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...